Company Profile
Basking Biosciences is developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS). The company’s development candidate, DTRI-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF). Basking is co-developing a matched oligonucleotide reversal agent, DTRI-025, for as-needed, rapid reversal of DTRI-031. Basking’s paired therapy has the potential to significantly expand the population of patients that receive acute thrombolytic therapy and aligns perfectly with the urgent need in medicine for precision-based therapeutics in cardiovascular disease.
